What is exosome therapy?
A plain introduction to exosome therapy: what exosomes are, why researchers study them as a cell-free alternative to stem cells, and where regulation stands.

Key takeaways.
- Exosomes are extracellular vesicles, typically 30 to 150 nanometers across, released by cells.
- Exosome therapy uses vesicles isolated from selected donor cells rather than the living cells themselves.
- Most clinical development uses exosomes from mesenchymal stem cells (MSCs).
- Exosomes are non-living and cannot replicate, which is the main safety argument made for them over cell therapy.
- As of 2024, no exosome product has FDA approval for any indication. All therapeutic use is investigational.
- Most registered therapeutic trials are still early phase, focused on safety and preliminary signals.
What exosome therapy means
Exosomes are small extracellular vesicles, meaning membrane-bound particles that cells release to signal to other cells. They typically measure 30 to 150 nanometers in diameter.
Exosome therapy is the administration of vesicles that have been isolated from selected donor cells. The idea came from stem cell research. Investigators came to think that much of the activity of mesenchymal stem cells (MSCs) comes from the factors they secrete, not from the cells turning into new tissue. Exosomes carry many of those factors.
Why researchers compare exosomes with cell therapy
The main argument is safety. Living stem cells can divide, so cell therapy carries a theoretical risk that transplanted cells could form tumors. Exosomes have no genome and cannot replicate, so the course material describes this specific risk as not applying to them.
This is a theoretical advantage. It does not mean exosome products are proven safe, and it says nothing about whether they provide clinical benefit.
Where exosomes come from
MSC-derived exosomes dominate current clinical development. MSCs were first identified in bone marrow and have since been isolated from many tissues.
Exosomes from different tissue sources have overlapping but distinct characteristics. Source selection therefore affects biology, manufacturing and the regulatory path.
Regulatory and clinical status
In the United States, the FDA regulates exosome products as biologics under Section 351 of the Public Health Service Act. Developers must show safety and efficacy in controlled trials, manufacture under good manufacturing practice, and obtain a Biologics License Application approval before marketing.
As of 2024, no exosome-based therapeutic product has received FDA approval for any indication. ClinicalTrials.gov lists over 200 trials involving exosomes as therapeutic agents or diagnostic biomarkers. Most therapeutic trials are Phase I or II.
Educational content for healthcare professionals. Not a treatment recommendation. Exosome therapies are not FDA-approved for therapeutic use.
This guide covers the what and the why.
The how is taught live. The webinar and live training go deeper on:
- How MSC tissue sources compare in practice
- Reading a product's characterization and quality data
- How FDA rules apply to products marketed to clinics
- The global trial landscape by indication
Common questions.
Are exosomes FDA-approved?
How is exosome therapy different from stem cell therapy?
What cells are most exosome products derived from?
Sources
- Phinney, D. G., & Pittenger, M. F. (2017). Concise review: MSC-derived exosomes for cell-free therapy. Stem Cells, 35(4), 851-858.
- Théry, C., et al. (2018). Minimal information for studies of extracellular vesicles 2018 (MISEV2018). Journal of Extracellular Vesicles, 7(1), 1535750.
- Kordelas, L., et al. (2014). MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia, 28(4), 970-973.
Keep reading.
Exosome · 3 min read
How are exosomes thought to work?
The proposed mechanisms of exosomes in plain terms: cargo delivery, immune modulation, new vessel growth and cell signaling. Most of this evidence is preclinical.
Start the lessonExosome · 3 min read
Exosomes for osteoarthritis and musculoskeletal conditions: what the research shows
Why exosomes are being studied in joints, bone, tendon, muscle and spine, and why all musculoskeletal use remains investigational.
Start the lessonExosome · 3 min read
Exosomes in aesthetics: skin, hair and wound healing
What clinicians should know about exosomes in aesthetic medicine: the rationale for skin, hair and scars, the limits, and the regulatory position.
Start the lessonReady for the hands-on detail?
Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.